Lineage Cell Therapeutics’ (LCTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report released on Tuesday morning,Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.06) EPS.

Other equities analysts also recently issued reports about the stock. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday. Maxim Group decreased their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN:LCTX opened at $0.52 on Tuesday. Lineage Cell Therapeutics has a one year low of $0.48 and a one year high of $1.61. The firm has a market capitalization of $114.62 million, a P/E ratio of -4.33 and a beta of 1.21. The company has a fifty day moving average of $0.60.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of LCTX. GSA Capital Partners LLP bought a new stake in Lineage Cell Therapeutics during the third quarter worth about $84,000. MAI Capital Management lifted its position in Lineage Cell Therapeutics by 2.2% during the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after purchasing an additional 35,907 shares during the period. Raffles Associates LP lifted its position in Lineage Cell Therapeutics by 3.4% during the third quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock worth $4,081,000 after purchasing an additional 150,000 shares during the period. State Street Corp lifted its position in Lineage Cell Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after purchasing an additional 45,483 shares during the period. Finally, Barclays PLC lifted its position in Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after purchasing an additional 159,924 shares during the period. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.